| Description | SDMA (Symmetric dimethylarginine) is the most potent endogenous inhibitor of nitric oxide synthase (NOS), with higher levels in patients with end-stage renal disease (ESRD). |
| In vitro | SDMA inhibited dose dependently the NO synthesis in intact endothelial cells, whereas it had no effect on protein expression of NOS. This effect was associated with an increase in reactive oxygen species. Co-incubation with L-arginine but not D-arginine reversed the effect of SDMA on NOS pathway. Suggest that SDMA reduced the endothelial NO synthesis, probably by limiting L-arginine supply to NOS. It is concluded that SDMA might be a useful parameter for detecting patients in very early stages of chronic kidney disease and for determining their risk for developing cardiovascular disease[1]. |
| Synonyms | NG,NG'-Dimethyl-L-arginine, Symmetric dimethylarginine, 对称N,N-二甲基精氨酸 |
| molecular weight | 202.25 |
| Molecular formula | C8H18N4O2 |
| CAS | 30344-00-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (247.22 mM) |
| References | 1. Bode-Boger, S. M . Symmetrical Dimethylarginine: A New Combined Parameter for Renal Function and Extent of Coronary Artery Disease[J]. Journal of the American Society of Nephrology, 2006, 17(4):1128-1134. 2. Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA). |